Novel Biotechnology Inc.

Based in Canada and founded in 2021 by co-founders Pankaj Khanna, Todd Morgan, Konstantin Rodionov, and Santhosh Kallivalappil, Novel Biotechnology Inc. specializes in the production and customization of plasmid DNA for research, preclinical, and industrial applications. In September 2023, Novel Biotechnology Inc. raised USD 2.

5 million in seed funding from the Ontario Centre of Innovation, with participation from individual investors. The core product offerings of Novel Biotechnology include custom plasmid DNA construction, plasmid DNA manufacturing, rapid plasmid prep services, plasmid QC and analytics services, and DNA sequencing services. These services cater to a wide range of research needs, with a commitment to delivering reliable and cost-effective solutions. Their capabilities encompass denovo synthesis of complex plasmid designs, cell line generation, fermentation, downstream processing, analytical characterization, and secure delivery of plasmid materials to clients.

 The company also offers a proprietary NBx platform that boasts microbial strains optimized for plasmid DNA production, distinct from conventional E. coli strains. The platform offers faster growth rates, high plasmid productivities, enhanced plasmid stability, and superior product quality profiles, all while seamlessly integrating with existing upstream and downstream infrastructure.   The company plans to use the September 2023 funding to expand its existing plasmid services business and expedite its platform R&D initiatives.